Strategic Partners Potential collaboration opportunities with large biopharma companies seeking immunotherapy platforms and predictive biomarkers, leveraging Jounce’s Translational Science Platform and existing pipeline to enhance combination therapy strategies.

Clinical Programs Opportunity to engage in or sponsor early to mid-stage trials around JTX-8064, vopratelimab, and JTX-4014 combinations, aligning with oncology centers of excellence and trial networks focused on tumor-associated macrophage reprogramming and ICOS/PD-1 pathways.

Mature Assets Consider inorganic opportunities around JTX-1811 licensing and related assets with Gilead, exploring parallel de-risking deals, equity investments, or co-development arrangements to leverage established mechanisms in CCR8-targeted T regulatory cell depletion.

Biomarker Focus Sales angles centered on biomarker-driven patient selection, offering companion diagnostic opportunities and data-sharing collaborations to strengthen market access, real-world evidence generation, and precision immuno-oncology strategies.

Strategic Financing Assess financing or strategic partnerships that support pipeline acceleration post-merger with Redx Pharma, including licensing, milestone-based funding, or co-commercialization discussions to maximize value from a combined immunotherapy portfolio.